若生智能
Drug Database
IN

indometacin (IV) (Indocin IV)

✓ Approved

Merck & Co. · PTGS1 · 小分子

什么是 indometacin (IV)？

indometacin (IV) 是一种小分子，由Merck & Co.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Indocin IV
公司Merck & Co.
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Merck & Co.

作用机制

分子靶点

indometacin (IV) 作用于 2 个分子靶点：

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

indometacin (IV) 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersPatent ductus arteriosus✓ Approved

相关研究文献

PubMedFrontiers in oncology2026-08-06

Palliative gastrectomy or gastrojejunostomy for symptomatic stage IV gastric cancer: a dual center, retrospective, propensity matched cohort study.

Zhang Xiaojie X, Ren Hu H, Zhang Lin L, Li Zongze Z et al.

Palliative surgery is considered to release symptoms for symptomatic stage IV gastric cancer (GC) patients. However, whether palliative gastrectomy or gastrojejunostomy should be conducted was still controversial. Therefore, the current study aims to compare the long-term prognosis of palliative gastrectomy and gastrojejunostomy for symptomatic stage IV GC patients. Symptomatic stage IV GC patients in the China-Japan Friendship Hospital and China National Cancer Center between January 2000 to December 2023 were retrospectively reviewed. The short-term safety and long-term survival outcomes were compared between palliative gastrectomy and gastrojejunostomy for symptomatic stage IV GC patients. A 1:1 propensity score matching (PSM) was performed to balance covariates between groups. In total, 2705 gastric cancer with stage IV were retrieved and finally 197 individuals were therefore enrolled in the study based on the search and inclusion and exclusion criteria. Compared with palliative gastrectomy group, palliative gastrojejunostomy group had shorter operation time (P < 0.001) and lower proportion of intraoperative blood transfusion (37 [32.174%] vs. 9 [14.516%], P = 0.011). While no significant difference was observed about postoperative complications between the two groups. Multivariate survival analysis demonstrated similar prognosis for symptomatic stage IV GC patients who underwent palliative gastrectomy or palliative gastrojejunostomy before (HR: 1.215, 95%CI: 0.859~1.717, P = 0.270) and after (HR: 0.756, 95%CI: 0.526~1.087, P = 0.131) applying PSM. Palliative gastrectomy might provide no survival benefit compared with Gastrojejunostomy for symptomatic stage IV gastric cancer. However, further multicenter, prospective studies with a larger sample size were needed to verify these findings.

PMID 42558416
阅读全文 →
PubMedTargeted oncology2026-08-06

Subcutaneous Amivantamab and Lazertinib in PALOMA-3: Efficacy, Safety, and Administration: A Vodcast.

Nguyen Danny D

Intravenous (IV) amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody, is approved for multiple indications alone or in combination for patients with EGFR-mutated advanced or metastatic nonsmall cell lung cancer (NSCLC). In the PALOMA-3 study, subcutaneous (SC) amivantamab was investigated to improve tolerability, reduce administration time, maintain efficacy, and improve patient experience. This vodcast reviews the rationale and data supporting SC amivantamab on the basis of the PALOMA-3 study and provides expert-led recommendations for SC amivantamab treatment. The PALOMA-3 study investigated the noninferiority of pharmacokinetics, with other endpoints including efficacy and safety of SC versus IV amivantamab, combined with lazertinib in participants with EGFR-mutated, advanced NSCLC after disease progression on osimertinib and platinum-based chemotherapy. Geometric mean ratios of Ctrough for SC to IV amivantamab were 1.15 at Cycle 2 Day 1 (C2D1) and 1.42 at C4D1; C2AUCD1-D15 was 1.035. Objective response rate (ORR) was 30% in the SC group and 33% in the IV group; median progression-free survival was 6.1 and 4.3 months, respectively. SC amivantamab resulted in fewer patients reporting infusion-related reactions (IRR; 13% versus 66% IV) and venous thromboembolism (VTE; 9% versus 14%) with prophylactic anticoagulation; shorter administration time at C1D1 (< 5 min per SC injection versus ~ 5 h for IV); and higher patient-reported convenience at the end of treatment (85% versus 35%). We discuss clinical considerations for SC amivantamab dosing and administration, including premedications, prophylactic measures, dose modifications, management of adverse reactions, and switching between IV and SC amivantamab. In conclusion, SC amivantamab demonstrated noninferior pharmacokinetics and antitumor responses compared with IV amivantamab in the PALOMA-3 study. SC amivantamab also reduced IRR and VTE, with shorter treatment administration times and enhanced patient convenience compared with IV. Utilizing SC amivantamab, while optimizing treatment efficacy and safety through mitigating and managing adverse events, may enhance the patient experience.

PMID 42557400
阅读全文 →
PubMedJournal of paediatrics and child health2026-08-06

HOMEFREE: Scaling-Up Evidence-Based Guidelines for IV-to-Oral Antibiotic Switch in Hospitalised Children, an Implementation Study Protocol.

Suna Jessica J, Tanti Daniel D, Bartlett Adam A, Blyth Christopher C et al.

Around half of children admitted to hospital receive intravenous (IV) antibiotics, contributing to higher costs, vascular access complications and longer hospital stays. A single-site pilot in a tertiary Australian paediatric hospital implemented nationally endorsed Australasian Stewardship of Antimicrobials in Paediatrics (ANZPID-ASAP) IV-to-oral antibiotic switch guidelines, improving timely switch rates from 64% to 82%. Following this success, a broader study is planned to assess the feasibility of scaling this approach across hospitals of varying types and sizes within NSW, Australia. The HOMEFREE study hypothesises that implementation of an IV-to-oral antibiotic switch programme based on endorsed guidelines and supported by audit and feedback will increase the proportion of hospitalised children transitioned to oral therapy or antibiotic cessation within 24 h of meeting eligibility criteria. The study will evaluate both effectiveness and implementation feasibility across tertiary paediatric and general hospitals in metropolitan and rural/regional settings. This paper presents the study protocol. Participating sites will select context-appropriate interventions to support guideline-concordant prescribing, informed by shared learning during the prospective phase. Effectiveness will be assessed using prospective audits, with key outcomes including timely guideline-concordant IV-to-oral switch and hospital length of stay. Implementation feasibility will be evaluated using the Consolidated Framework for Implementation Research through surveys of local project committee members conducted before and after 12 months of audit and feedback. This study will assess the effectiveness and feasibility of translating and scaling best-practice IV-to-oral antibiotic switch guidelines for children in real-world hospital settings.

PMID 42557787
阅读全文 →
PubMedJournal of nephrology2026-08-06

Repeat kidney biopsy unmasks the transition from active inflammation to irreversible damage in lupus nephritis: longitudinal outcomes from a single-center cohort in Egypt.

Fetouh Mohammed G MG, Sabry Alaa A, Fouda Mohammed A MA, Abdulrahim Mona M

Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus, and repeat kidney biopsy has a potential value in monitoring disease progression and impact on treatment adjustments. We retrospectively analyzed 81 Egyptian LN patients who underwent two kidney biopsies at the Urology and Nephrology Center, Mansoura University, between January 2011 and April 2024. Indications included persistent proteinuria, active urinary sediment, or unexplained renal impairment. Demographic, clinical, laboratory, histological, and treatment data were collected. Pathology was assessed using the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification, activity and chronicity indices, and outcomes were analyzed by Cox regression. At repeat biopsy, pathological transitions occurred in 48%. The transition toward more severe disease categories was frequent and included: Class I/II to III/IV: 7 of 10 patients, Class III to IV: 6 of 11 patients, Class III/IV + V to IV: all 3 patients, Class IV to VI: 5 of 49 patients, Class V to III/IV/VI: 6 of 8 patients. The activity index decreased (median 12→7, P < .001), while chronicity increased (2→4, P < .001). Treatment escalation was needed in 53.1% of patients. Over a median follow-up of 5.4 years, 56.8% progressed to kidney failure. Serum creatinine at both biopsies independently predicted kidney failure (Hazard ratio [HR] 1.24, P = .007; HR 1.22, P < .001). Shorter biopsy intervals were protective (HR 0.97, P < .001). At the second biopsy, chronicity index, glomerulosclerosis, and cellular crescents independently predicted kidney failure. Repeat biopsy is of pivotal importance in LN, unmasking critical histological transitions and shifts towards chronicity that can guide essential therapy changes and improve prognostication beyond clinical assessment alone.

PMID 42560667
阅读全文 →
PubMedJournal of veterinary pharmacology and therapeutics2026-08-06

Pharmacokinetics, Amino Acid Responses, and Short-Term Tolerability of Intravenous and Oral L-Citrulline in Healthy Neonatal Holstein Calves.

Gültekin Mehmet M, Boyacıoğlu Murat M, Erdoğan Hasan H, Ural Kerem K et al.

L-citrulline is a precursor for endogenous arginine synthesis, supporting nitric oxide production and urea cycle function, yet its pharmacokinetics in neonatal calves are unknown. This study characterized and compared the pharmacokinetics of L-citrulline after intravenous (IV) and oral (PO) administration in healthy neonatal Holstein calves and evaluated associated amino acid responses and short-term clinical and laboratory tolerability. Six healthy male calves (2-4 weeks old) received a single 150 mg/kg dose of L-citrulline as extemporaneously prepared 5% (w/v) IV and 10% (w/v) PO formulations in a randomized 2-period crossover design with a 7-day washout. Blood samples were collected pre-dose and up to 48 h post-dose. Plasma amino acids were quantified by LC-MS/MS, and pharmacokinetic parameters were estimated using non-compartmental analysis. After IV administration, the highest observed total plasma L-citrulline concentration was detected at the first post-dose sampling time, 5 min after bolus administration (Cpeak 2213 ± 629 μmol/L; range, 1329-2830 μmol/L). After PO administration, Cmax was 1107 ± 371 μmol/L (range, 623-1478 μmol/L), with a median Tmax of 60 min (range, 45-120 min). Baseline-corrected non-compartmental analysis yielded t1/2 values of 2.32 ± 0.79 h after IV administration and 2.23 ± 0.60 h after PO administration, with AUC0-∞ values of 4130 ± 558 and 3444 ± 1067 μmol·h/L, respectively. Absolute oral bioavailability was 0.86 ± 0.32 (range, 0.52-1.28). Both routes increased plasma arginine (max +159% IV; +122% PO) and ornithine (max +132% IV; +149% PO) with no clinically relevant adverse effects or laboratory abnormalities during short-term monitoring of clinical, hematological, biochemical, blood gas/electrolyte, and coagulation variables. These findings support further evaluation of L-citrulline as a nutritional and/or therapeutic supplement in neonatal calves.

PMID 42560683
阅读全文 →
PubMedFrontiers in immunology2026-08-06

Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosing.

Agundez-Moreno Alex A, Presas-Rodríguez Silvia S, González-García Antonio Manuel AM, Teniente-Serra Aina A et al.

Natalizumab (NTZ) is a high-efficacy therapy for relapsing-remitting multiple sclerosis (RRMS) that can be administered intravenously (IV) or subcutaneously (SC). While switching from IV to SC NTZ is increasingly common in clinical practice, evidence on pharmacodynamic stability, particularly under extended interval dosing (6 weeks), remains limited. This study aimed to evaluate CD49d receptor occupancy (RO), serum neurofilament light chain (sNfL) levels, and clinical outcomes in RRMS patients switching from IV to SC NTZ while maintaining either 4- or 6-week dosing intervals. We conducted a multicenter, ambispective, observational study including RRMS patients who had received IV NTZ for at least 6 months on a 4w or 6w schedule and subsequently switched to SC NTZ while maintaining the same dosing interval. CD49d RO was assessed in CD4+, CD8+, and CD19+ lymphocyte subsets before the first, third, and seventh SC administrations. sNfL levels and clinical outcomes (relapses, MRI activity, EDSS score) were also evaluated. Mixed models for repeated measures were applied. A total of 48 patients were included (4w: n=20; 6w: n=28). CD49d RO remained stable over time within both dosing schedules across all lymphocyte subsets. A significant difference between groups was observed only in CD19+ cells at the third administration (LS mean difference 13.08, SE = 4.10; p=0.028; 95% CI: 4.90-21.26) without clinical correlation. sNfL levels showed no significant differences at any timepoint within or between groups. Clinically, patients remained stable, with no new MRI activity or disability progression during the follow-up. Switching from IV to SC NTZ while maintaining either standard (4w) or extended (6w) dosing intervals preserves pharmacodynamic stability, as reflected by sustained CD49d RO, stable sNfL levels, and consistent clinical outcomes. These findings support SC administration as a reliable alternative to IV NTZ, including in extended interval dosing strategies.

PMID 42558353
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多indometacin (IV)